辉瑞公司将生产瑞德昔韦,增加产能

2020-08-09 Allan MedSci原创

辉瑞制药公司近日宣布与吉利德科学公司(Gilead Sciences)达成了一项协议,以生产吉利德开发的抗病毒药物瑞德昔韦(remdesivir),以帮助应对COVID-19大流行。

辉瑞制药公司近日宣布与吉利德科学公司(Gilead Sciences)达成了一项协议,以生产吉利德开发的抗病毒药物瑞德昔韦(remdesivir),以帮助应对COVID-19大流行。根据协议,辉瑞公司将在其堪萨斯州麦克弗森市的工厂提供合同制造服务,以为吉利德生产和供应瑞德昔韦。

辉瑞公司首席执行官Albert Bourla表示:“从一开始,显然没有任何一家公司能够终结COVID-19危机。这就需要这个制药产业系统共同提供解决方案”。目前尚不清楚辉瑞是否只向美国市场供货。

同时,吉利德的目标是到今年年底生产足够数量的瑞德昔韦,以治疗超过200万名COVID-19患者,而美国最近已购买了截至9月的几乎所有抗病毒药物。吉利德说,该药的生产网络已经发展到北美、欧洲和亚洲的40多家公司,以增强产能。

5月,吉利德(Gilead)与五家仿制药生产商达成了许可协议,以在127个国家(不包括美国)生产瑞德昔韦。此后,该协议已扩展到包括Hikma Pharmaceuticals在内的九家制药商,后者表示已开始在其葡萄牙工厂生产瑞德昔韦。吉利德在六月表示,在美国和其他发达国家,瑞德昔韦的定价为每瓶390美元,5天为一个疗程,共6瓶,每位患者需支付2340美元。

原始出处:

https://www.firstwordpharma.com/node/1747460?tsid=4

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1517831, encodeId=6773151e83176, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573594, encodeId=7ffd15e359448, content=<a href='/topic/show?id=f6b768e230b' target=_blank style='color:#2F92EE;'>#瑞德昔韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68723, encryptionId=f6b768e230b, topicName=瑞德昔韦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807256, encodeId=5cf480e256f2, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 10 11:54:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807098, encodeId=c07480e098d9, content=加油加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200822/b4ea7b614a2f44058d2ee7550da5aa99/0a410f15b95946019df4b84086b90665.jpg, createdBy=64642447770, createdName=123eaf1bm35暂无昵称, createdTime=Sun Aug 09 13:54:22 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807094, encodeId=508f80e09446, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caa55135459, createdName=14665664m21暂无昵称, createdTime=Sun Aug 09 13:34:53 CST 2020, time=2020-08-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1517831, encodeId=6773151e83176, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573594, encodeId=7ffd15e359448, content=<a href='/topic/show?id=f6b768e230b' target=_blank style='color:#2F92EE;'>#瑞德昔韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68723, encryptionId=f6b768e230b, topicName=瑞德昔韦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807256, encodeId=5cf480e256f2, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 10 11:54:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807098, encodeId=c07480e098d9, content=加油加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200822/b4ea7b614a2f44058d2ee7550da5aa99/0a410f15b95946019df4b84086b90665.jpg, createdBy=64642447770, createdName=123eaf1bm35暂无昵称, createdTime=Sun Aug 09 13:54:22 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807094, encodeId=508f80e09446, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caa55135459, createdName=14665664m21暂无昵称, createdTime=Sun Aug 09 13:34:53 CST 2020, time=2020-08-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1517831, encodeId=6773151e83176, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573594, encodeId=7ffd15e359448, content=<a href='/topic/show?id=f6b768e230b' target=_blank style='color:#2F92EE;'>#瑞德昔韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68723, encryptionId=f6b768e230b, topicName=瑞德昔韦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807256, encodeId=5cf480e256f2, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 10 11:54:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807098, encodeId=c07480e098d9, content=加油加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200822/b4ea7b614a2f44058d2ee7550da5aa99/0a410f15b95946019df4b84086b90665.jpg, createdBy=64642447770, createdName=123eaf1bm35暂无昵称, createdTime=Sun Aug 09 13:54:22 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807094, encodeId=508f80e09446, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caa55135459, createdName=14665664m21暂无昵称, createdTime=Sun Aug 09 13:34:53 CST 2020, time=2020-08-09, status=1, ipAttribution=)]
    2020-08-10 ms5000002046462755

    好消息

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1517831, encodeId=6773151e83176, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573594, encodeId=7ffd15e359448, content=<a href='/topic/show?id=f6b768e230b' target=_blank style='color:#2F92EE;'>#瑞德昔韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68723, encryptionId=f6b768e230b, topicName=瑞德昔韦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807256, encodeId=5cf480e256f2, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 10 11:54:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807098, encodeId=c07480e098d9, content=加油加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200822/b4ea7b614a2f44058d2ee7550da5aa99/0a410f15b95946019df4b84086b90665.jpg, createdBy=64642447770, createdName=123eaf1bm35暂无昵称, createdTime=Sun Aug 09 13:54:22 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807094, encodeId=508f80e09446, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caa55135459, createdName=14665664m21暂无昵称, createdTime=Sun Aug 09 13:34:53 CST 2020, time=2020-08-09, status=1, ipAttribution=)]
    2020-08-09 123eaf1bm35暂无昵称

    加油加油

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1517831, encodeId=6773151e83176, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1573594, encodeId=7ffd15e359448, content=<a href='/topic/show?id=f6b768e230b' target=_blank style='color:#2F92EE;'>#瑞德昔韦#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68723, encryptionId=f6b768e230b, topicName=瑞德昔韦)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Aug 11 02:53:25 CST 2020, time=2020-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807256, encodeId=5cf480e256f2, content=好消息, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6d095409783, createdName=ms5000002046462755, createdTime=Mon Aug 10 11:54:44 CST 2020, time=2020-08-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807098, encodeId=c07480e098d9, content=加油加油, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200822/b4ea7b614a2f44058d2ee7550da5aa99/0a410f15b95946019df4b84086b90665.jpg, createdBy=64642447770, createdName=123eaf1bm35暂无昵称, createdTime=Sun Aug 09 13:54:22 CST 2020, time=2020-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=807094, encodeId=508f80e09446, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=caa55135459, createdName=14665664m21暂无昵称, createdTime=Sun Aug 09 13:34:53 CST 2020, time=2020-08-09, status=1, ipAttribution=)]
    2020-08-09 14665664m21暂无昵称

    0

相关资讯

辉瑞的Vyndaqel首次在欧洲获批用于治疗淀粉样变心肌病ATTR-CM

欧洲委员会(EC)已批准将辉瑞的Vyndaqel(tafamidis)用于患有野生型或遗传性转甲状腺素蛋白淀粉样变心肌病(ATTR-CM)的成年人。

辉瑞罕见病创新药维达全在中国获批

全球首个转甲状腺素蛋白稳定剂口服制剂维达全于2月5日获得中国国家药品监督管理局批准

康希诺生物与辉瑞就有望获批的四价脑膜炎球菌结合疫苗进行合作

7月25日,康希诺生物股份公司(以下简称“康希诺生物”)和辉瑞投资有限公司(以下简称“辉瑞”)在上海共同签署了推广服务协议。康希诺生物自主研发的四价脑膜

2020 Q1各大药企收入排名,强生,罗氏,诺华,默沙东,辉瑞,礼来,阿斯利康......

4月份,强生,礼来,GSK,辉瑞、诺华、默沙东相继发布了2020年第一季度财报。在疫情的笼罩之下,今年注定是不平凡的一年。而对于跨国药企而言,其开年业绩就上演了“王座更迭”的戏

辉瑞的美罗华仿制药RUXIENCE的营销申请,获得欧盟人用药物委员会的积极评价

辉瑞公司宣布,其美罗华(利妥昔单抗)的潜在的生物仿制药RUXIENCE的营销授权申请,获得欧洲药品管理局(EMA)的人用药品管理委员会(CHMP)的积极意见。

辉瑞也加入到新型冠状病毒COVID-19疫苗的研发阵营

辉瑞公司首席科学官Mikael Dolsten表示,正在与BioNTech进行合作,以利用其基于mRNA的药物开发平台开发COVID-19疫苗。

拓展阅读

瑞德昔韦联合血浆来源中和抗体:开展III期临床评价抗新冠病毒COVID-19的有效性

福奇博士表示:“ ITAC试验将评价在雷姆昔韦中添加中和抗体的增强作用,以期在疾病早期抑制SARS-CoV-2,从而将感染抑制在萌芽状态。”

吉利德开始测试吸入型瑞德昔韦

吉利德(Gilead)宣布了一项计划,开始对吸入型抗病毒药物瑞德昔韦(remdesivir)进行试验,以期在COVID-19的治疗途径中尽早使用该药物。

重症新冠肺炎患者应用瑞德昔韦有获益!新英格兰医学杂志研究:需谨慎对待,不能过早乐观

当前,针对新冠病毒感染,尚无有效的治疗药物,全球各国研究人员都在寻找有效治疗药物。